Herpesvirus, such as Herpes simplex virus (HSV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), and Kaposi's sarcoma-associated herpesvirus (KSHV), are closely engaged in a broad spectrum of human diseases ranging from acute infection to immune dysregulation and tumor. There are also herpesviruses that can impact animals. There is no proven or effective treatment for those Herpesvirus-associated diseases, highlighting the urgency to further delineate the interaction of virus and host. After initial infection, all herpesviruses remain latent within specific host cells and may subsequently reactivate. Clinical syndromes due to primary infection can vary significantly from those caused by reactivation of these viruses. Herpesviruses do not survive long outside a host; thus, transmission usually requires intimate contact. In people with latent infection, the virus can reactivate without causing symptoms; in such cases, asymptomatic shedding occurs and people can transmit infection. Despite the fact that the herpesviruses are genetically and structurally similar, they cause a wide array of generally non-overlapping clinical syndromes. In contrast to other herpesviruses, which are not known to cause malignancy, Epstein-Barr virus (EBV) and human herpesvirus type 8 (HHV-8), also known as Kaposi sarcoma–associated herpesvirus (KSHV), can cause certain cancers.
There are continuous and ongoing efforts in understanding the structural features and mode of action of these pathogens, vital in driving scientific discovery and treatment strategies against these infections. Through this research topic, we aim to explore the scientific gaps associated with our understanding of herpesvirus and its importance to design better drug and treatment modalities.
The current Research Topic aims to highlight the latest scientific findings on these pathogens in the following areas:
1. Mode of transmission between the hosts.
2. Pathogenesis and resistance mechanisms developed by the species.
3. Host-pathogen interaction and immune evasion mechanisms.
4. Novel treatment strategies against the infection.
Herpesvirus, such as Herpes simplex virus (HSV), Epstein-Barr virus (EBV), Cytomegalovirus (CMV), and Kaposi's sarcoma-associated herpesvirus (KSHV), are closely engaged in a broad spectrum of human diseases ranging from acute infection to immune dysregulation and tumor. There are also herpesviruses that can impact animals. There is no proven or effective treatment for those Herpesvirus-associated diseases, highlighting the urgency to further delineate the interaction of virus and host. After initial infection, all herpesviruses remain latent within specific host cells and may subsequently reactivate. Clinical syndromes due to primary infection can vary significantly from those caused by reactivation of these viruses. Herpesviruses do not survive long outside a host; thus, transmission usually requires intimate contact. In people with latent infection, the virus can reactivate without causing symptoms; in such cases, asymptomatic shedding occurs and people can transmit infection. Despite the fact that the herpesviruses are genetically and structurally similar, they cause a wide array of generally non-overlapping clinical syndromes. In contrast to other herpesviruses, which are not known to cause malignancy, Epstein-Barr virus (EBV) and human herpesvirus type 8 (HHV-8), also known as Kaposi sarcoma–associated herpesvirus (KSHV), can cause certain cancers.
There are continuous and ongoing efforts in understanding the structural features and mode of action of these pathogens, vital in driving scientific discovery and treatment strategies against these infections. Through this research topic, we aim to explore the scientific gaps associated with our understanding of herpesvirus and its importance to design better drug and treatment modalities.
The current Research Topic aims to highlight the latest scientific findings on these pathogens in the following areas:
1. Mode of transmission between the hosts.
2. Pathogenesis and resistance mechanisms developed by the species.
3. Host-pathogen interaction and immune evasion mechanisms.
4. Novel treatment strategies against the infection.